OBJECTIVE: To observe the effect of Zaoren Anshen capsules in treating senile insomnia and changes in its hemorheology. METHOD: A total of 120 patients with senile insomnia were randomly divided into the Zaoren Anshen capsules group (five capsules, n = 60) and the Alprazolam group (0.8 mg, n = 60) for treatment and control observation. Pittsburgh sleep quality index (PSQI) was used for evaluating clinical efficacy in the first and fourth week before and after treatment. RESULT: The Zaoren Anshen capsules group had lower higher scores in PSQI (5.91 +/- 1.37) than that before treatment (13.49 +/- 3.87), with great statistical significant in difference (P < 0.01). The alprazolam group had lower higher scores in PSQI than that before treatment, with great statistical significant in difference (P < 0.01). apart from higher PSQI scores in the Zaoren Anshen capsules group than that of the Alprazolam group after treatment for one week (P < 0.05), the comparison between the Zaoren Anshen capsules group and the alprazolam group before and after treatment for four weeks showed no statistical significance. As for hemorheological parameters, the difference in the whole blood viscosity (including high-shear, middle-shear and low-shear) of patients in the Zaoren Anshen capsules showed great statistical significance before and after treatment (P < 0.01), and so did the plasma viscosity (P < 0.05). Zaoren Anshen capsules showed less adverse reactions than alprazolam. CONCLUSION:Zaoren Anshen capsules have similar effect in treating senile insomnia with alprazolam, with less adverse reactions. They are so suitable for patients with senile insomnia that they can improve hemorheological indicators of patients with senile insomnia and have good effect in promoting circulation and removing stasis.
RCT Entities:
OBJECTIVE: To observe the effect of Zaoren Anshen capsules in treating senile insomnia and changes in its hemorheology. METHOD: A total of 120 patients with senile insomnia were randomly divided into the Zaoren Anshen capsules group (five capsules, n = 60) and the Alprazolam group (0.8 mg, n = 60) for treatment and control observation. Pittsburgh sleep quality index (PSQI) was used for evaluating clinical efficacy in the first and fourth week before and after treatment. RESULT: The Zaoren Anshen capsules group had lower higher scores in PSQI (5.91 +/- 1.37) than that before treatment (13.49 +/- 3.87), with great statistical significant in difference (P < 0.01). The alprazolam group had lower higher scores in PSQI than that before treatment, with great statistical significant in difference (P < 0.01). apart from higher PSQI scores in the Zaoren Anshen capsules group than that of the Alprazolam group after treatment for one week (P < 0.05), the comparison between the Zaoren Anshen capsules group and the alprazolam group before and after treatment for four weeks showed no statistical significance. As for hemorheological parameters, the difference in the whole blood viscosity (including high-shear, middle-shear and low-shear) of patients in the Zaoren Anshen capsules showed great statistical significance before and after treatment (P < 0.01), and so did the plasma viscosity (P < 0.05). Zaoren Anshen capsules showed less adverse reactions than alprazolam. CONCLUSION:Zaoren Anshen capsules have similar effect in treating senile insomnia with alprazolam, with less adverse reactions. They are so suitable for patients with senile insomnia that they can improve hemorheological indicators of patients with senile insomnia and have good effect in promoting circulation and removing stasis.